Cognition Therapeutics rises as it extends access to rare brain disorder drug

Cognition Therapeutics

05/02/2026 12:41

** Shares of drug developer Cognition Therapeutics CGTX.O rise 1.9% to $1.05 premarket

** Co says it extended its access program for zervimesine, an experimental drug for Lewy body dementia - a disorder that affects movement, thinking and behavior

** Co says the program now allows patients to stay on the daily 100 mg oral drug for several more months beyond the original one‑year plan

** Program began in June 2025 and has enrolled 32 patients across eight U.S. sites

** Co recently finished a mid‑stage study in Lewy body dementia and discussed results with the FDA; meeting minutes expected this month - CGTX

** CGTX's zervimesine is also being studied in Alzheimer’s and age‑related macular degeneration, says co

** Shares up ~93% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))